Refractory Ovarian Carcinoma Recruiting Phase 1 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0110942 (Refractory Ovarian Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04840589Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsTreatment